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The transcription factor early B cell factor-1 (Ebf1) is
a key determinant of B lineage specification and
differentiation. To gain insight into the molecular
basis of Ebf1 function in early-stage B cells, we
combined a genome-wide ChIP sequencing analysis
with gain- and loss-of-function transcriptome anal-
yses. Among 565 genes that are occupied and tran-
scriptionally regulated by Ebf1, we identified large
sets involved in (pre)-B cell receptor and Akt
signaling, cell adhesion, and migration. Interestingly,
a third of previously described Pax5 targets was
found to be occupied by Ebf1. In addition to Ebf1-
activated and -repressed genes, we identified targets
at which Ebf1 induces chromatin changes that poise
the genes for expression at subsequent stages of
differentiation. Poised chromatin states on specific
targets could also be established by Ebf1 expression
in T cells but not in NIH 3T3 cells, suggesting that Ebf1
acts as a ‘‘pioneer’’ factor in a hematopoietic chro-
matin context.
INTRODUCTION
The differentiation of highly specialized, hematopoietic lineage
cells from hematopoietic stem cells (HSCs) involves regulated
expression of lineage-specific factors and concomitant loss of
alternate lineage potential. In adult bone marrow, lymphopoiesis
initiates with the generation of lymphoid-primed multipotent
progenitors (LMPPs) that differentiate into common lymphoid
progenitors (CLPs), a heterogeneous cell population containing
cells that already express select markers of the B cell lineage
(Inlay et al., 2009). From the CLP population, pre-pro-B cells,
also termed Fraction A cells, are generated and further differen-
tiate into pro-B cells. These cells, also known as Fraction B cells,
are characterized by the upregulation of B lineage markers
including CD19 and the immunoglobulin (Ig) surrogate light
chains VpreB and l5, initiation of Ig heavy chain gene rearrange-
ment and proliferation in response to interleukin-7 (IL-7)714 Immunity 32, 714–725, May 28, 2010 ª2010 Elsevier Inc.(reviewed in Hardy et al., 2007; Murre, 2009). Pre-B cells express
the pre-B cell receptor (pre-BCR) and further differentiate into
immature B cells that have undergone Ig light chain gene rear-
rangement and migrate from the bone marrow to the spleen.
Each of these B cell differentiation steps is dependent on
the coordinated expression of cell-type-specific transcription
factors and activities of signaling pathways (reviewed in Mandel
and Grosschedl, 2010). Genetic ablation and complementation
studies have demonstrated key roles for transcription factors
such as Ikaros, Pu.1, E2A, early B cell factor-1 (Ebf1), and
Pax5 (reviewed in Busslinger, 2004; Hagman and Lukin, 2006;
Singh et al., 2007). Prior to the differentiation of CLPs, Ikaros
and Pu.1 induce the expression of components of signaling
pathways, including Il7 and Flt3, which are necessary for the
generation of pro-B cells (DeKoter et al., 2002; Yoshida et al.,
2006). Several lines of evidence demonstrate the requirement
for E2A (Tcf3) and Ebf1 (Ebf1) in the specification of the B cell
lineage. Targeted inactivation of either Tcf3 or Ebf1 results in
a similar block of early B cell differentiation, and a synergistic
relationship of these two factors has been inferred from the
analysis of compound heterozygous mice that display more
severe phenotypes than single heterozygous mice (Bain et al.,
1994; Lin and Grosschedl, 1995; O’Riordan and Grosschedl,
1999; Zhuang et al., 1994). Moreover, forced expression of
Ebf1 in hematopoietic progenitors promotes B cell development
at the expense of other lineages (Medina et al., 2004; Zhang
et al., 2003). Pax5 has been shown to act as a determinant of
B cell commitment, given that Pax5-deficient pro-B cells display
uncharacteristic lineage plasticity and are able to generate non-
lymphoid cell types (Nutt et al., 1999).
Because Ebf1 plays a pivotal role in early developmental
processes of the B cell lineage and functions at the intersection
of its initial specification and subsequent commitment, much
work has focused on characterizing this transcription factor.
Ebf1 is expressed in all stages of B lymphopoiesis with the
exception of terminally differentiated plasma cells (Hagman
et al., 1993). In addition, Ebf1 is expressed and has a functional
role in neuronal and adipocyte lineages (Jimenez et al., 2007;
Wang et al., 1997). Targeted inactivation of Ebf1 results in the
complete block at the pre-pro B cell stage, and induced expres-
sion of Ebf1 is sufficient to restrict HSCs to the B cell lineage or to
overcome blocks in B cell differentiation resulting from the loss of
factors such as Il7 (Il7), Ikaros (Ikzf1), PU.1 (Sfpi1), or E2A (Tcf3)
Figure 1. Ebf1 Directly Binds and Functionally Regulates Target
Gene Promoters in B Cells
(A and B) SignalMap view of the location and enrichment of Ebf1-binding
regions within the Pou2af1 promoter by ChIP of A-MuLV-transformed pro-B
cells (A) or primary pro-B cells (B).
(C) Transcriptional regulation of bound Ebf1 targets shown by qRT-PCR in
a gain-of-function approach. Ebf1/ pre-pro-B cells were infected with an
Ebf1-IRES-EGFP or a control EGFP retrovirus, and a set of 50 Ebf1-bound
genes was examined for expression 24 hr after transduction. Fold expression
is displayed as values relative to the empty vector control.
(D) qRT-PCR analysis of Ebf1-bound targets regulated in a loss-of-function
approach. Ebf1 was deleted by tamoxifen treatment of Ebffl/flRERT-Cre pro-
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et al., 2007; Zhang et al., 2003). In part, Ebf1 acts through the
regulation of downstream targets such as Pax5, Cd79a (formerly
known as mb-1), Blk, Vpreb1, Igll1(l5), Cd19, Pou2af1 (OCAB),
and Foxo1 (O’Riordan and Grosschedl, 1999; Sigvardsson
et al., 2002; Zandi et al., 2008). Although Ebf1 functions to
promote B lineage specification, Ebf1 is also an important factor
in the repression of alternative cell fates. Ectopic Ebf1 expres-
sion promotes B cell development in multipotent progenitor
(MPP) cells and antagonizes myeloid and T cell differentiation
in Pax5/ progenitor cells, whereby Ebf1 downregulates the
expression of myeloid determinants including Cebpa, Sfpi1,
and Id2 (Pongubala et al., 2008; Thal et al., 2009). Finally, Ebf1
has been suggested to act as a ‘‘pioneer factor’’ in gene regula-
tion by controlling the epigenetic status and resulting accessi-
bility of target genes (Maier et al., 2004). In studies of the Ebf1
target gene Cd79a, Ebf1 has been shown to contribute to epige-
netic regulation of the promoter through CpG demethylation and
nucleosomal remodeling, thus allowing accessibility to addi-
tional transcriptional regulators (Maier et al., 2004).
Although it is clear that Ebf1 acts as a determinant of the
specification and commitment of the B cell lineage through the
direct and indirect regulation of several downstream targets,
our current understanding is not sufficient to fully account for
both loss- and gain-of-function phenotypes. To gain further
insight into the underlying molecular mechanisms of Ebf1 func-
tion, we have utilized multiple genome-wide analyses aimed at
identifying not only directly bound Ebf1 targets, but also targets
that are functionally regulated by Ebf1.
RESULTS
Genome-wide Mapping of Ebf1 Binding in Promoter
Regions by ChIP-on-Chip Analysis
To identifydirect targetsofEbf1 inpro-Bcells,weadoptedachro-
matin-immunoprecipitation (ChIP) strategy using an Ebf1 anti-
body and hybridization with DNA tiling arrays that represent
1.73 104 promoter regions (2kb to +0.5kb relative to the tran-
scription start site) of RefSeq genes. We first examined the
enrichment of the well-characterized Ebf1-binding sites in the
Cd79a and Igll1 promoters (Figure S1A available online). Quanti-
tation of the immunoprecipitated fragments by quantitative PCR
(qPCR) showed that these Ebf1-bound chromatin fragments
were enriched more than 1000-fold relative to two randomly
chosen intergenic control regions (Figure S1B). Duplicate ChIP-
on-chip analyses with Abelson murine leukemia virus (A-MuLV)-
transformed pro-B cells and primary pro-B cells showed robust
and reproducible binding of Ebf1 to a subset of promoters
including several known Ebf1 targets. For example, Ebf1 strongly
bound upstream of the transcriptional start site (TSS) of the
Pou2af1 gene in both cell types (Figures 1A and 1B). In primary
pro-B cells, we detected 207 Ebf1 binding events in the tiled
promoters corresponding to 228 potential target genes, given
that some promoter regions reside between two genes onB cells and cells were collected after complete loss of Ebf1 protein at day 5
for analysis of the same 50 Ebf1-bound genes as in (C). Fold expression is dis-
played as values relative to heterozygote control cells. Genes common to both
gain- and loss-of-function studies are underlined (C andD). See also Figure S1.
Immunity 32, 714–725, May 28, 2010 ª2010 Elsevier Inc. 715
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Genome-wide Ebf1 Target Gene Analysisopposing DNA strands (Table S1). From this data set, 50 putative
targets were selected for validation. Using qPCR analysis of the
two ChIP-samples from the array hybridization and a third inde-
pendent ChIP experiment, we could reproduce binding of Ebf1
to more than 90% of the 50 regions (Figure S1C).
Altered Expression of Ebf1-Bound Genes in Ebf1
Gain- and Loss-of-Function Experiments
To assess the functional relevance of the identified Ebf1-bound
genes, we usedboth Ebf1 gain- and loss-of-function approaches
in early B cells. For the induction of Ebf1 activity, we transduced
Ebf1/ pre-pro-B cells (Fraction A) with an Ebf1-expressing
retrovirus, which resulted in Ebf1 expression similar to that of
wild-type pro-B cells (Figure S1D). The cells were harvested
24 hr after infection, as previously described (Pongubala et al.,
2008), and assessed for transcripts from Ebf1 target genes by
qRT-PCR. In addition to the robust induction of known Ebf1
targets including Igll1 (data not shown) and VpreB, 19 of the 50
test set genes (38%) showed a more than two-fold expression
change compared to empty retrovirus-transduced controls, and
most genes were activated by Ebf1 (Figure 1C).
In a complementary set of experiments, we isolated pro-B
cells from mice carrying one or two floxed Ebf1 alleles and a
tamoxifen-inducible form of the cre recombinase (I.G. and R.G.,
unpublished data). Within 2 days of treatment with 4-hydroxy-
tamoxifen, the Ebf1 locus is efficiently inactivated, and within
5 days, Ebf1 protein is no longer detectable by immunoblot
analysis (data not shown). At this time point, the expression of
50 putative Ebf1 target genes in the test set was compared
between homo- and heterozygously-floxed cell cultures. The
expression of 34% (17 of 50) of the Ebf1-bound genes was
substantially changed, whereby most genes were downregu-
lated upon loss of Ebf1 (Figure 1D). Comparison of the gain-
and loss-of-function analyses reveals an overlap of ten genes
(20%of the test set) that are reciprocally regulated in both exper-
imental approaches. Therefore, these genes can be regarded as
direct Ebf1 targets with high confidence.
Genome-wide Analysis of Ebf1 Binding in Pro-B Cells
by ChIP Sequencing
Because only a fraction of transcription factor binding occurs
in promoter regions (Farnham, 2009), we analyzed anti-Ebf1-
immunoprecipitated DNA from A-MuLV-transformed pro-B cells
by deep-sequencing. Ebf1-bound and control input DNA were
analyzed, generating sequence reads sufficient to cover nearly
the entire genome. Comparison of Ebf1 and control data sets
with the CCAT peak-calling algorithm (Xu et al., 2010) identified
9561 significant peaks at a false discovery rate (FDR) < 0.01
that correspond to 5025 genes. Similar results were obtained
with two other peak-calling modules (Figure S2A). Moreover,
sequencing of an independent, replicate Ebf1 ChIP experiment
demonstrated the high reproducibility of our data (Pearson
correlation = 0.79), given that more than 94% of the bound
regions were also identified in the original ChIP-seq analysis
(Figure S2B). More than half of the Ebf1-bound sites identified
by ChIP-on-chip were found to be enriched in the ChIP-seq
experiment (Figure S2C), which is consistent with the overlap
reported for other comparisons of ChIP-on-Chip and Chip-seq
binding data (e.g., for nuclear hormone receptors, see Cheung716 Immunity 32, 714–725, May 28, 2010 ª2010 Elsevier Inc.and Kraus, 2010). Notably, ChIP-seq peaks that overlap with
Ebf1-bound regions in the ChIP-on-chip analysis showed higher
enrichment (Figure S2D), suggesting that discordant binding in
both assays is most likely due to differential identification of
weakly-bound regions. To increase the stringency of detection
and minimize false positive signals, we introduced a 3-fold
enrichment threshold for the anti-Ebf1-ChIP peaks based on
the comparison between sequenced tags in the Ebf1 library
and the control library. Thus, the final data set included 5071
high-confidence peaks that correspond to 3138 genes (Table
S2). Sharp peaks were identified at known Ebf1-binding sites,
such as the promoter of Cd79b, in both ChIP-seq replicates
(Figure 2A and Figure S2E). Binding of Ebf1 to the identified
peak regions could consistently be verified by qPCR on four
individual anti-Ebf1 ChIP samples from primary pro-B cell
cultures (Figure S2F). Overall, the distribution of Ebf1-binding
events throughout the genome showed a clear enrichment
within and in close proximity to genes, given that only 11% of
the bound regions lie more than 100 kb from the closest RefGene
(Figure 2B). Inspection of the binding site distribution in the region
around the TSS revealed preferential recruitment of Ebf1 to prox-
imal promoter sites (Figure 2C). Throughout our analysis,weused
two categories of potential Ebf1 targets. The first group (3138
genes) contains at least one Ebf1-binding site within 100 kb of
the gene body, whereas the second group (1470 genes) contains
at least one binding site within 10 kb of the TSS. Taken together,
the data sets generated by both ChIP-on-chip and ChIP-seq
identify a large number of Ebf1-bound sites near genes and
suggest a role for Ebf1 in the regulation of these targets.
Binding Site Occupancy of Ebf1 Is Tissue Specific
In the B cell lineage, Ebf1 has been proposed to act as ‘‘pioneer’’
factor that binds to gene loci even in the context of ‘‘closed’’ chro-
matin to initiate locus activation (Maier et al., 2004).BecauseEbf1
also plays important roles in other developmental processes
such as adipogenesis and neurogenesis, we examined whether
the regions bound by Ebf1 in B cells are specific for B lymphoid
genes or whether neuronal and adipocyte-specific loci are also
bound (Jimenez et al., 2007; Wang et al., 1997). Using publicly
available microarray data, we assembled independent lists of
genes that showed preferential expression in B cells, in other
hematopoietic cell lineages that do not express Ebf1, and in non-
hematopoietic Ebf1-expressing tissues. The incidence of Ebf1-
bound regions close to genes in these lists was then compared
to a random background gene set. From this comparison, B
cell-specific genes were the most highly enriched of the three
gene sets, with Ebf1 bound within 10 kb from the TSS of more
than 20% of the genes (p < 2.2 3 1016). Interestingly, other
hematopoietic lineage-specific genes also contained amarkedly
enriched number of Ebf1-bound regions, whereas genes specific
for nonhematopoietic Ebf1-expressing tissueswere not enriched
(Figure 2D). This finding indicates that Ebf1 binding is tissue
specific and suggests that Ebf1 does not occupy binding sites
in ‘‘silenced’’ chromatin.
Coenrichment of Binding Sites for Ebf1 and Other
Hematopoietic Transcription Factors
The binding site for Ebf1 was previously defined as a palindromic
repeat of the sequence 50-ATTCCC-30 with a spacer of two
Figure 2. ChIP Sequencing Reveals Direct
Binding of Ebf1 to Genomic Regions Corre-
sponding to Hematopoietic Genes
(A) Sequence tag profile of the genomic region
surrounding the Ebf1 binding site in the Cd79b
promoter. RefGenes are indicated, and average
tag counts per 100 bp bins are plotted.
(B) Distribution of Ebf1-bound regions identified
by ChIP-seq in relation to annotated gene loci.
A schematic diagram of a gene locus displays the
relative abundance of Ebf1-binding sites (TSS,
transcription start site; TES, transcription end site).
(C) Frequency of Ebf1-bound sites per 100 bp in
the regions 10 kb up- and down-stream of TSS.
(D) Association of Ebf1-bound regions with the
expression of tissue-specific genes. For each cell
type, preferentially expressed genes were identi-
fied based on the GNF Gene Expression Atlas.
The significance of the correlation was determined
by comparison to a random gene set (c2 test).
(E) Singlemost enrichedDNAsequencemotif iden-
tifiedwithWEEDER in an analysis of the 1000most
highly enriched, Ebf1-bound sequences identified
by ChIP-seq.
(F) Graphical representation of the frequency of
the Ebf1-binding motif in relation to the center
position of all Ebf1-binding peaks.
(G) Overrepresented transcription factor binding
motifs within all Ebf1 binding regions (±150bp
from peak center) were identified with position
weighed matrices from the TRANSFAC database.
p values represent the enrichment of each binding
motif in comparison to the local background.
Percentages represent a secondary analysis for
calculating the proportion of gene-associated
Ebf1-bound regions that also contain the given
transcription factor binding motif (e < 0.0001).
(H) Genes regulated by the transcription factor
Pax5 were compiled from published studies.
Percentages represent the proportion of the
Pax5-regulated genes that lie within 100 kb of an
Ebf1-bound region. p values represent a compar-
ison to a random gene set (c2 test). See also
Figure S2.
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Genome-wide Ebf1 Target Gene Analysisnucleotides between the two half-sites (Travis et al., 1993). A de
novo search for enriched sequence motifs in the sequences
underlying the Ebf1-bound peaks yielded a similar but shortened
binding site with the two first nucleotides of the reported half-site
appearing to be dispensable for in vivo binding (Figure 2E). The
Ebf1 motif is found in 88% of the bound regions (e < 0.0005)
with the motif instances strongly enriched around the center of
the Ebf1 peaks (Figure 2F). This observation suggests that the
palindromic sequence 50-TCCCNNGGGA-30 is the only relevant
Ebf1-binding motif in vivo.Immunity 32, 714–7To identify factors that potentially
collaborate with Ebf1 in the regulation of
transcription, we scanned the Ebf1-
bound regions for the presence of over-
represented transcription factor binding
motifs using the TRANSFAC database
(Matys et al., 2006). Seven motifs or
groups of related binding motifs of tran-scription factors known to be involved in hematopoiesis were
found to be strongly enriched in this sequence set (Figure 2G,
Figure S2G, and Table S3). Notably, binding sites of all transcrip-
tion factors that have been described as functional ‘‘collabora-
tors’’ of Ebf1 are found among the enriched motifs. In particular,
E2A has been shown to genetically and functionally interact with
Ebf1 (O’Riordan and Grosschedl, 1999; Sigvardsson et al.,
2002). Moreover, a functional interaction between Ebf1 and
Runx1 was shown on the Cd79a promoter, on which Ets1 and
Pax5 also collaborate in an Ebf1-dependent manner (Maier25, May 28, 2010 ª2010 Elsevier Inc. 717
Figure 3. Direct Ebf1 Binding Is Strongly Associated
with Transcriptional Changes upon Perturbation of
Ebf1 Activity
(A) Comparison of the microarray data sets from Ebf1 gain- or
loss-of-function studies with genes associated with Ebf1-
bound regions identified by ChIP-seq.
(B) Validation of the gain-of-function transcriptome analysis.
Ebf1/ pre-pro-B cells were infectedwith empty or Ebf1-con-
taining retroviruses in triplicate as described above. Expres-
sion of Ebf1 functional targets identified in the gain-of-function
microarray that also contain Ebf1-binding sites within 100 kb
of the gene were determined by qRT-PCR and are shown rela-
tive to empty vector-infected cells.
(C)Quantitationof thenumberof Ebf1-bound regions identified
by ChIP-seqwithin 100 kb of genes upregulated in the gain-of-
function experiment. Gray bars correspond to all RefGenes;
blue bars correspond to those induced by Ebf1 expression.
(D) Overlap of Ebf1-bound genes (ChIP-seq peakwithin 100 kb
of thegene) also identified as functional targetsbyEbf1gain- or
loss-of-function analyses. Genes activated by Ebf1 are dis-
played in blue, repressed genes in red. See also Figure S3.
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Genome-wide Ebf1 Target Gene Analysiset al., 2003; Maier et al., 2004). These data suggest that Ebf1
cooperates not only with previously described, but also with
additional transcription factors in target gene regulation.
Ebf1 Binding Correlates with Gene Regulation by Pax5
The enrichment of Pax5-binding sites within the Ebf1-bound
regions prompted us to examine whether genes regulated by
Pax5 are also enriched for Ebf1 binding. To this end, we
compared published data sets of Pax5-activated and -repressed
genes (Delogu et al., 2006; Pridans et al., 2008; Schebesta et al.,
2007) with genes associated with Ebf1-bound genomic regions.
Interestingly, Pax5-activated, and to a minor extent also Pax5-
repressed, genes have a markedly increased frequency of
Ebf1-occupied sites compared to a random gene set (Figure 2H
and Table S4). This finding suggests that the network control of B
lymphopoiesis by Ebf1 and Pax5 involves not only cross-regula-718 Immunity 32, 714–725, May 28, 2010 ª2010 Elsevier Inc.tion of these transcription factors (Decker et al.,
2009; Roessler et al., 2007) but also their concerted
binding and regulation of target genes.
Ebf1 Binding Correlates Strongly
with Transcriptional Regulation
To link the identified Ebf1 binding sites to the
function of Ebf1 in transcriptional regulation, we
performed microarray expression analyses on
Ebf1/ pre-pro-B cells retrovirally transduced
with Ebf1 (gain-of-function [GoF]) and Il7-cultured
pro-B cells with conditionally inactivated Ebf1
(loss-of-function [LoF]) (Figures S3A and S3B and
Tables S5 and S6). These experiments provided
us with three genome-wide data sets whose
comparisons and overlaps could be used to identify
direct, transcriptional targets of Ebf1. In a first step,
the regulated RefGenes from each microarray
experiment were matched with the ChIP-seq bind-
ing data. Genes containing an Ebf1-bound region
within 100 kb of the gene body aswell as the subsetshowing Ebf1 binding within 10 kb of the TSS show a substantial
enrichment among the Ebf1-regulated genes identified by the
microarray experiments (Figure 3A). More specifically, in com-
paring our gain-of-function results with the ChIP-seq data set,
15% of Ebf1-occupied genes were regulated, whereas our
loss-of-function experiment showed regulation of 14% of the
Ebf1-bound genes.
Although the correlation with activated genes is significantly
stronger than with repressed targets (p = 1.27 3 103 / 4.06 3
104 for the LoF 100 kb/10 kb sets), a clear link exists between
direct Ebf1 binding and transcriptional repression. For validation
of the gain-of-function microarray experiment, the expression
changes of the most strongly up- and downregulated genes
that lie close to a mapped Ebf1-binding site were examined
by qRT-PCR (Figure 3B). In this experiment, we could verify
the repression of eight out of nine Ebf1 target genes and the
Immunity
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also noted that genes containing more than one Ebf1-binding
site within 100 kb are more likely to be regulated by Ebf1;
such a result may be related to a cumulative or cooperative
effect of multiple Ebf1 molecules bound to a particular gene
locus (Figure 3C). Together, the collection of three genome-
wide data sets reveals that approximately one-quarter of Ebf1-
bound targets are also regulated by Ebf1 at the transcriptional
level.
Overlap of Three Different Genome-wide Data Sets
Defines High-Confidence Targets of Ebf1
Comparison of the gain- and loss-of-function microarray data
shows only a modest overlap of 137 Ebf1-activated and 60
Ebf1-repressed genes whose expression is consistently altered
in both experimental settings (Figure S3C). To identify Ebf1-
bound genes among these high-confidence targets, we aligned
the overlapping set of Ebf1-activated RefGenes (114 out of
the 137 consistently activated genes) with the ChIP-seq data,
resulting in a 68% match (77/114) (Figure 3D). Together with a
similar alignment of Ebf1-repressed genes, 92 genes (77 acti-
vated and 15 repressed) were identified in all three target
gene analyses, whereby 60 activated and 7 repressed genes
contain occupied Ebf1-binding sites within 10 kb from the tran-
scription start site, including genes identified in the initial ChIP-
on-chip analysis (Table 1 and Table S7). This core gene set
represents a ‘‘gold standard’’ collection of genes that are
directly regulated by Ebf1.
Ebf1 Preferentially Regulates Components of Signal
Transduction Cascades
The core set of Ebf1 targets can be grouped into seven
broad functional categories according to available annotations
(Table 1). Interestingly, approximately half of the genes are
related to the cellular signal transduction machinery ranging
from surface receptors to transcription factors. To confirm this
observation, we performed a statistical analysis using annota-
tions from the PANTHER database and found that three closely
related biological processes are strongly overrepresented: intra-
cellular signaling, protein modification, and protein phosphoryla-
tion (Figure S4A). In particular, components of B cell receptor
signaling were enriched, and so were components of T cell
receptor signaling, many of which are shared between both
pathways (Figure S4B). Inspection of the more than 50 potential
Ebf1 targets within the BCR signaling pathway showed a higher
proportion of Ebf1-bound genes in the proximal part of the BCR
signaling cascade (Figure S4C). Moreover, a large number of
these Ebf1-bound genes are regulated in our functional analysis,
most of them being activated in the gain-of-function experiment.
Together, these results suggest that one of the cardinal functions
of Ebf1 is the establishment of the B cell-specific signal trans-
duction network.
Chromatin Structure at Promoters that Are Activated,
Repressed, or Poised by Ebf1
The large number of in vivo binding sites for Ebf1 identified in this
study represents a valuable resource for studies concerning the
mechanisms of Ebf1 function. In a first approach, we grouped
Ebf1-bound genes into three categories: genes activated byEbf1, genes repressed by Ebf1, and genes that are bound
by Ebf1 in early-stage B cells, but are not transcriptionally active
until the mature B cell stage. For those genes not immediately
activated by Ebf1, we predicted that Ebf1 functions to prepare
the target genes for future expression and establish a ‘‘poised’’
state. For each of the three target categories, representative
genes were chosen on the basis of their response in the gain-
and loss-of-function experiments and on their expression pat-
terns at different stages of B cell differentiation (Figures 4A–4C).
In ChIP experiments, we used antibodies specific for covalent
modifications of histone H3 that represent marks of accessible
and transcribed chromatin (H3K4me3 and H3Ac) or silenced
chromatin (H3K27me3). In this analysis, we also examined
H3K4me2 modification, which has been associated with
‘‘poised’’ chromatin, similar to H3K4me3-H3K27me3 ‘‘bivalent’’
chromatin (Bernstein et al., 2006; Orford et al., 2008). We deter-
mined the chromatin state of these genes at the transcriptional
start sites and the Ebf1-binding sites (if located more than 1 kb
from the TSS) in Ebf1-deficient pre-pro-B cells, in Ebf1-positive
pro-B cells, and in mature splenic B cells (Figures 4D–4F). As ex-
pected, the Ebf1-activated targets Cd79a, Gfra2, and Pax5
gain H3K4 methylation and H3 acetylation marks upon the
transition to the pro-B stage, correlating with their transcriptional
activation (Figure 4D). The genes that show amarked downregu-
lation in pro-B cells relative to pre-pro-B cells (Figure 4B), and
that are repressed after retroviral transduction of Ebf1 into
Ebf1/ pre-pro-B cells, show a loss of activating chromatin
marks and gain of H3K27 trimethylation between the pre-pro-B
and pro-B cell stages (Figure 4E).
Finally, in a third set of genes, includingCd40, Acp5, and Egr3,
we do not observe transcriptional activation in Ebf1-expressing
cells until the mature B cell stage (Figure 4C). Interestingly, we
detect two stages of chromatin alterations, one corresponding
with the binding of Ebf1 in pro-B cells and the other with tran-
scriptional activation at the mature B cell stage. Specifically,
the chromatin at the Ebf1-binding sites gains H3K4 dimethyla-
tion during the transition of pre-pro-B cells to pro-B cells
(Figure 4F). ForAcp5 andEgr3, in which the Ebf1-binding regions
reside some 8 kb upstream of the TSS, these changes may
reflect the chromatin ‘‘opening’’ at cis-regulatory elements in
Ebf1-positive cell stages. The H3K4me3 and H3Ac activation
marks only appear in mature B cells, coinciding with transcrip-
tional activation (Figure 4F). We observe a similar pattern of
histone modifications in the promoter region of the Cd40 gene
in which the Ebf1-binding site resides 435 bp upstream of the
TSS. In the pro-B stage, a robust H3K4me2 signal is detected,
then activation marks are found in mature B cells (Figure 4F).
Together, these data show that direct target binding by Ebf1 is
linked to chromatin modifications that either precede transcrip-
tional activation, or correlate with gene activation or repression.
Ebf1 ‘‘Poises’’ Chromatin Structure Independent
of Transcription
To analyze the direct effects of Ebf1 binding on the surrounding
chromatin without the changes induced by transcriptional acti-
vation or cellular differentiation, we transduced a CD4+CD8+
T cell progenitor line and the fibroblastic NIH 3T3 cell line with
an Ebf1-encoding retrovirus or a control virus. Twenty-four hours
after gene transfer, we performed a ChIP assay to monitorImmunity 32, 714–725, May 28, 2010 ª2010 Elsevier Inc. 719
Table 1. Genes that Are Consistently Activated or Repressed in
the Ebf1 Gain- and Loss-of-Function Experiments and that Are
Bound by Ebf1 within 10 kb of the Transcription Start Site in the
ChIP-Seq and/or ChIP-on-Chip Studies
Gene Symbol Accession No.
Transcription and Regulation
Bhlha15 NM_010800
Cbx2 NM_007623
Ell3 NM_145973
Foxo6 NM_194060
Hes1 NM_008235
Hes5 NM_010419
Mterfd3 NM_028832
Parp1 NM_007415
Pold4 NM_027196
Pou2af1 NM_011136
Zfpm1 NM_009569
Receptors and Signal Transduction
Bst1 NM_009763
Cd72 NM_001110320
Ceacam1 NM_001039185
Cmtm8 NM_027294
Dok3 NM_013739
Dtx1 NM_008052
Gpr56 NM_018882
Gpr97 NM_173036
Icosl NM_015790
Igll1 AK137514
Notch3 NM_008716
P2rx3 NM_145526
Pde4a NM_183408
Plekhg2 NM_001083912
Rgs12 NM_173402
Rinl NM_177158
Sit1 NM_019436
Spred2 NM_033523
Trfr2 NM_015799
Vpreb1 NM_016982
Vpreb2 NM_016983
Kinases and Phosphatases
Blk NM_007549
Dusp7 NM_153459
Pkig NM_001039390
Ptp4a3 NM_008975
Ptprs NM_011218
Sbk1 NM_145587
Enzymes and Metabolism
Agpat9 NM_172715
Aldh3b1 NM_026316
B3gnt2 NM_016888
Impdh1 NM_011829
Neu1 NM_010893
Table 1. Continued
Gene Symbol Accession No.
Pck2 NM_028994
Pitpnm2 NM_011256
Membrane Transport
Kcna5 NM_145983
Mfsd4 NM_172510
Ucp2 NM_011671
Cytoskeleton and Motility
Asb2 NM_023049
Atp8b3 NM_026094
Cyfip2 NM_133769
Itgb7 NM_013566
Micall2 NM_174850
Rsph9 NM_029338
Sema7a NM_011352
Smtn NM_001159284
Miscellaneous
2010317E24Rik NM_001081085
4632428N05Rik NM_028732
Bcl7a NM_029850
Ccdc18 NM_028481
Chchd10 NM_175329
Fam102a NM_153560
Lrmp NM_008511
Mreg NM_001005423
Srl NM_175347
Stxbp1 NM_001113569
Zc3h12d NM_172785
Repressed targets are shown in bold, and all other genes are activated
targets. See also Figure S4.
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720 Immunity 32, 714–725, May 28, 2010 ª2010 Elsevier Inc.binding of Ebf1 at Cd79a and Pax5, genes that are activated by
Ebf1 in pro-B cells, and at Egr3 and Cd40, genes that are
‘‘poised’’ for expression in later stage B cells. We observed
binding of exogenously expressed Ebf1 to the sites identified
by ChIP-seq in the Beko cells. Notably, we detected no tran-
scription or transcriptional activation of Cd79a, Pax5, and Egr3,
whereas Cd40 was activated to low expression by Ebf1 (Figures
5A and 5B). In NIH 3T3 cells, we detected no substantial binding
of Ebf1, despite the similar expression of Ebf1 and an active
transcriptional state of Egr3 in the NIH 3T3 cells (Figures 5C
and 5D; data not shown). Together with the ChIP-seq analysis,
which indicated that binding of endogenous Ebf1 in pro-B cells
is enriched for T cell-specific genes but not nonhematopoietic
genes, these results indicate that Ebf1 recognizes binding sites
in a hematopoietic chromatin context, independent of an active
transcriptional state.
Analysis of histone modifications revealed a marked increase
in H3K4 dimethylation at the Ebf1-bound regions of all four genes
specifically in Ebf1-expressing Beko cells (Figure 5E). Consistent
with the lack of robust transcription from the four test genes, no
enrichment of H3K4 trimethylation could be observed, whereas
H3K4 di-and trimethylation was detected at a housekeeping
Figure 4. Ebf1 Activity Generates Active,
Repressed, or Poised States of Gene
Expression that Are Reflected by Alter-
ations in Chromatin Status
(A–C) Transcript expression of select Ebf1-bound
genes that are activated (A), repressed (B), or
poised (C) for expression by Ebf1 were analyzed
in three stages of B cell development. Percent-
ages displayed are relative to the cell type with
the maximum expression value for each gene.
Error bars represent standard deviation of tripli-
cate qRT-PCRs.
(D–F) ChIP analysis of four histone modifications
in the cell types shown in (A). The promoter
regions and the Ebf1-bound regions identified in
this study for each gene shown in (A)–(C) were
analyzed by qPCR. Percentages are relative to
the cell typewith the highest enrichment for a given
modification in each bound region. The location
relative to the transcriptional start site (in base
pairs) is given for each Ebf1-bound region within
an upstream regulatory element. Only modifica-
tions shown to have greater than 5-fold enrich-
ment over a nonspecific control region are shown.
Fr.A, Ebf1/ pre-pro-B cells; pro-B, Il7 cultured
pro-B cells; and Mat.B, B220+ splenic B cells.
See also Figure S5.
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of H3K4 di- or trimethylation upon Ebf1 expression at the sites
tested. The chromatin at the Egr3 gene contained bothmodifica-
tions at the transcription start site (Figure 5F), which is consistent
with its transcriptional activity. The upstream enhancer is not
modified, which suggests a different and Ebf1-independent
regulation in the fibroblastic cells. Taken together, these data
suggest that Ebf1 binds to lineage-specific target sites in a hema-
topoietic chromatin context and induces changes in chromatin
that poise the genes for subsequent transcriptional activation.
DISCUSSION
The combination of genome-wide analyses of Ebf1-bound and
-regulated genes allows for a comprehensive view into the
molecular basis of Ebf1 function in B lineage cells. Although
Ebf1 has been identified as a determinant of B lymphocyte spec-
ification and differentiation, the number of known target genesImmunity 32, 714–has been limited (reviewed in Lukin
et al., 2008). Our ChIP-seq analysis indi-
cated that Ebf1 occupies 4500 sites
within 100 kb of annotated genes.
Previous analysis of transcription factor
(TF) binding in embryonic stem cells has
shown that binding site numbers for
a given TF can range between 1,126 for
Smad1 and 39,609 for CTCF (Chen
et al., 2008). Such large numbers of occu-
pied binding sites do, however, raise the
question of functional relevance and
necessitate their interrogation by tran-
scriptome analysis. Comparison of ourChIP-seq data with two independent, functional analyses
showed that 26% of the genes containing Ebf1-binding sites
within 100 kb were also transcriptionally regulated. In addition
to a small subset of genes that are conversely regulated in
gain- and loss-of-function experiments, this comparison of
genome-wide data sets also indicated that several genes require
Ebf1 only for the initiation of expression. For example, Cd79a
and b (encoding Iga and b), Gcgr (coding for the glucagon
receptor), and others are markedly upregulated in the gain-of-
function experiment, but are not affected by the inactivation of
Ebf1. Another interesting set of genes was identified by
comparing Ebf1-bound genes with published data sets in which
differential gene expression was examined in pro-B cells and
mature B cells versus CLPs (Mansson et al., 2008). In particular,
for several Ebf1-occupied genes, expression is detected at later
stages of differentiation, but not in Ebf1-positive pro-B cells.
Thus, these genes represent targets on which Ebf1 appears to
play a role in ‘‘poising’’ chromatin for expression.725, May 28, 2010 ª2010 Elsevier Inc. 721
Figure 5. Ebf1-Binding Requires a Hematopoietic Chromatin
Context and Directly Leads to Local Chromatin Activation
Beko T cells (A, B, and E) and NIH 3T3 cells (C, D, and F) were infected with an
Ebf1-IRES-GFP expressing retrovirus or control virus and sorted for GFP
expression 24 hr after infection. (A) and (C) show analysis of Ebf1-binding to
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722 Immunity 32, 714–725, May 28, 2010 ª2010 Elsevier Inc.In previous studies, targeted gene inactivation of Ebf1 and
retroviral transduction of hematopoietic progenitor cells indi-
cated that Ebf1 regulates the earliest steps of B lymphopoiesis,
including specification (Lin and Grosschedl, 1995; Pongubala
et al., 2008). However, the initially identified target genes do
not fully account for the presumed roles of Ebf1 in this process.
In the hematopoietic system, both transcription factors E2A and
Ebf1 are markedly upregulated in the B lymphoid progenitor
population of the CLP compartment (Inlay et al., 2009). Ebf1
has been shown to induce the expression of the Tcf3 gene and
conversely, E2A can activate the Ebf1 gene (Kee and Murre,
1998; Zhuang et al., 1994). In our ChIP-seq analysis, we identi-
fied three Ebf1-binding sites in the Tcf3 gene and conditional
inactivation of Ebf1 results in a marked downregulation of Tcf3.
Likewise, the transcription factor Bcl11a has been identified as
a determinant of B cell differentiation that acts upstream of
Ebf1 (Liu et al., 2003). We found three Ebf1-binding sites in the
Bcl11a locus and detected an increase of Bcl11a expression in
the gain-of-function experiment. Thus, Ebf1, E2A, and Bcl11a
appear to act in a concerted manner to establish the early B
cell program in which pairs of regulatory factors are intercon-
nected by feedback loops that stabilize developmental lineage
decisions. Another interconnection in this network control is
provided by the reciprocal regulation of the Ebf1 and Pax5 genes
and the binding of Ebf1 to a relatively large portion of Pax5
targets (Decker et al., 2009; Roessler et al., 2007; this study).
An important aspect of B cell differentiation is the commitment
step in which alternative cell fates are repressed. Pax5 has been
shown to act as themajor determinant of this process asPax5/
cells gain developmental plasticity and are able to differentiate
into alternative lineages (Nutt et al., 1999; Urba´nek et al.,
1994). Recently, Ebf1 has also been implicated in the repression
of alternative cell fates as it was found that Ebf1 can repress
the Cebpa, Sfpi1, Id2, and Id3 genes independently of Pax5
(Pongubala et al., 2008; Thal et al., 2009). Our combined ChIP-
sequencing and microarray experiments provide additional
insight into the potential function of Ebf1 in lineage restriction.
Ebf1 was found to directly repress the homeobox gene Hlx,
encoding a protein that collaborates with Tbet to promote Th1
differentiation (Mullen et al., 2002). Moreover, we identified
Pdcd1, Ctla4, and Icosl as genes that are directly repressed by
Ebf1. Pdcd1 and Ctla4 encode members of the CD28 family of
receptors that are expressed on T lymphocytes and regulate
T cell activation and tolerance (Greenwald et al., 2005). Likewise,
the ligand of the Icos receptor regulates T helper cell differentia-
tion and humoral immune responses (Greenwald et al., 2005).an intergenic control region, the Tpi promoter, and four Ebf1 target genes
by anti-Ebf1 ChIP and qPCR. 50 Egr3 represents the Ebf1 binding region
7869 bp upstream of the TSS, whereas the other amplicons are located in
the proximal promoter regions. Error bars represent standard deviation of
duplicate ChIP experiments. (B) and (D) show qRT-PCR expression analysis
of Ebf1 targets in Beko (B) and NIH 3T3 cells (D) retrovirally transduced with
Ebf1 or an empty vector control. Raw cycle values of the qRT-PCR were
normalized to Tpi expression and are displayed as fold expression compared
with mature splenic B cells. Error bars represent standard deviation of exper-
imental triplicates. (E) and (F) show quantification of H3K4 di- (light green) and
trimethylation (dark green) of the regions analyzed in (A) by ChIP and qPCR.
Empty virus controls are shown in light and dark gray. Error bars represent
standard deviation of duplicate ChIP experiments.
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been implicated in the restriction of alternative lineage choices
(Pongubala et al., 2008; Thal et al., 2009), we identified Gfi1b
as an Ebf1-repressed gene. Gfi1b encodes a transcriptional
repressor that is under cross-regulatory feedback control with
its relative Gfi1, which has been shown to promote B lineage
fate choices (Spooner et al., 2009; Vassen et al., 2007). Consis-
tently, Gfi1, which itself is not bound by Ebf1, is downregulated
upon loss of Ebf1 in pro-B cells, presumably via upregulation
of the Ebf1-bound Gfi1b gene. Thus, Ebf1 is an important
regulatory component of multiple transcriptional networks that
specify the B lineage fate.
The most prominent cluster of Ebf1-bound and -regulated
genes includes components of the (pre)BCR signaling pathway.
Previously, several genes, including Cd79a and Cd79b, VpreB,
Igll1, and Blnk, were identified as Ebf1 targets (reviewed in Lukin
et al., 2008). Our genome-wide analysis allowed for the identifi-
cation of an additional 21 Ebf1-occupied and -regulated genes
common to this pathway. Moreover, 75 genes implicated in
various aspects of (pre)BCR signaling are bound by Ebf1. These
Ebf1-regulated genes include components of the (pre)BCR
receptor complex and receptors that modulate and fine-tune
BCR signals, such as Cd72 and Cd19 (reviewed in Brezski and
Monroe, 2008). In addition to several important BCR down-
stream components, such as Blk and Plcg, Ebf1 regulates
other signaling events that are initiated by BCR stimulation. In
particular, the genes encoding components of Ca2+ signaling,
such as the IP3 receptor, PKC, and Dok3, a negative regulator
of Jnk activation and Ca2+ mobilization (reviewed in Mashima
et al., 2009), are direct Ebf1 targets. Another Ebf1-regulated
and BCR-linked signaling cascade includes the PI3 kinase
pathway. This pathway has been recently shown to regulate
BCR-mediated cell survival, whereby constitutively active PI3
kinase was found to rescue the survival of cells in which the
BCR has been conditionally inactivated (Srinivasan et al.,
2009). Notably, Ebf1 directly regulates genes encoding compo-
nents that link the PI3 kinase pathway to BCR signaling,
including Cd19 and the genes encoding BCAP (Pik3ap1) and
Bank1 (Bank1), which were up- and downregulated, respec-
tively. Pik3ap1 encodes an adaptor protein that potentiates
Akt signaling by regulating PI3K localization, whereas Bank1
encodes a negative regulator of Akt activation (Aiba et al.,
2006; Okada et al., 2000). In our analysis, we noticed that the
coincidence of Pax5 regulation and Ebf1 binding is most exten-
sive for genes involved in (pre)BCR signaling, the key signaling
pathway in lymphocytes. This observation may reflect an ‘‘over-
wiring’’ of this pathway and explain why many of the genes are
not affected upon conditional Ebf1 inactivation
Ebf1 has been implicated in epigenetic regulation by initiating
DNA demethylation at theCd79a gene (Maier et al., 2004). More-
over, Ebf1 has been found to associate with components of the
Swi/Snf2 nucleosome-remodeling complex (Gao et al., 2009).
The inability of Ebf1 to occupy known adipocyte- or neuronal-
specific target genes in pro-B cells indicates that Ebf1, despite
its suggested role as ‘‘pioneer factor,’’ requires a permissive
chromatin context for binding. This notion was confirmed by
the binding of Ebf1 to B cell-specific genes upon expression in
hematopoietic T lineage cells but not in fibroblastic NIH 3T3 cells.
The permissive chromatin context could be generated by Ebf1binding with other cell type-specific transcription factors and
concomitant recruitment of chromatin-modifying complexes or
by the establishment of a hematopoietic chromatin ‘‘signature’’
in HSCs. The latter view is consistent with the promiscuous
expression of genes in HSCs, which has been attributed to a
‘‘multi-lineage priming’’ of genes (Hu et al., 1997; Miyamoto
et al., 2002).
The developmental dynamics in the chromatin state of several
Ebf1-target genes that are activated, repressed, or poised for
expression by Ebf1 revealed an increase in activating chromatin
marks and a decrease in repressive marks on Ebf1-activated
genes. Conversely, genes that are expressed in Ebf1-deficient
pre-pro-B cells, but are repressed in Ebf1-positive pro-B and
mature B cells, show Ebf1-associated decreases in activating
histone marks and increases of repressive marks. Because
these chromatin changes are associated with alterations in
gene expression, our analysis does not allow for conclusions
about a potential role of Ebf1 in epigenetic regulation. However,
an interesting Ebf1-bound gene set, including Cd40 and Egr3, is
expressed in mature B cells, but not in pro-B cells. In these
genes, Ebf1-binding is associated with the appearance of H3K4
dimethyl marks independent of gene expression. The poised
chromatin state can be recapitulated in T lineage cells upon
ectopic expression of Ebf1, showing that its establishment
does not require B cell differentiation. Notably, the two Ebf1
target genes Cd79a and Pax5, which are rapidly activated at
the onset of Ebf1 expression in early-stage B cells, exhibit
a poised chromatin state in T cells that have been transduced
with an Ebf1-expressing retrovirus. Taken together, our data
reveal three distinct events involved in gene regulation by Ebf1.
First, binding of Ebf1 is dependent on a permissive hematopoi-
etic chromatin context, given that no binding of Ebf1 to its B
cell gene targets is observed in fibroblastic cells. Second,
binding of Ebf1 induces changes in chromatin structure including
histonemodifications that ‘‘poise’’ target gene loci in a transcrip-
tion-independent manner. In particular, H3K4 dimethylation has
been associated with ‘‘poised’’ chromatin (Orford et al., 2008),
and our data suggest that Ebf1 is a transcription factor that is
involved in targeting this chromatin mark to specific genes.
Lastly, collaboration with other transcription factors and cofac-
tors allows Ebf1 to direct the ultimate transcription state of target
genes throughout B cell differentiation.
EXPERIMENTAL PROCEDURES
Chromatin Immunoprecipitation and ChIP-on-Chip
Anti-Ebf1 chromatin-IP (ChIP) was performed essentially as previously
described (Pongubala et al., 2008). Detailed ChIP-protocols are included in
the Supplemental Experimental Procedures. DNA from aEbf1 chromatin IP
experiments was amplified in two steps with the whole-genome amplification
and reamplification kits (Sigma) and purified via a Qiaprep spin column
(QIAGEN). The resulting material and equally treated input control DNA were
labeled and hybridized to mm8 RefSeq promoter tiling arrays (Nimblegen)
by ImaGenes (Berlin). Data was analyzed using SignalMap (Nimblegen), and
the implemented FindPeaks algorithm was used for peak calling. A peak of
FDR < 0.05 in one experiment with an overlapping peak of FDR < 0.1 in the
duplicate experiment was scored as an Ebf1-bound region.
Deep Sequencing and Peak Calling
Libraries were prepared from 10 ng of Ebf1 ChIP DNA and input DNA, respec-
tively, in accordance with the manufacturer’s protocol. ChIP-seq data wereImmunity 32, 714–725, May 28, 2010 ª2010 Elsevier Inc. 723
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mapped to the mouse genome (mm8, NCBI) with ELAND (Illumina) and only
uniquely mapped tags (263 106 per library) were considered. For identifica-
tion of Ebf1-binding regions, tags with the same mapping coordinates were
counted as one to address possible amplification biases. The sequence tag
density generated from the input library was used as background. Regions
enriched in the Ebf1 ChIP sample were identified with CCAT (Xu et al.,
2010). Peaks with FDR < 0.01 were considered significant. Additionally, a
3-fold enrichment cut-off was imposed. Gene coordinates were obtained
from the UCSC RefGene table (mm8), and binding sites were mapped to the
nearest genes (up to a maximal distance of 100 kb). Information regarding
the additional bioinformatic analysis is provided in the Supplemental Experi-
mental Procedures.
Retroviral Expression of Ebf1
Retrovirus was produced by transient transfection of Plat-E cells with retroviral
constructs encoding Ebf1-EGFP (pMYs-Ebf1-IRES-EGFP) or EGFP alone
(pMYs-IRES-EGFP). The supernatant was collected 24 hr and 48 hr after trans-
fection and supplemented with 10 mg/ml polybrene. For spin infection, the
target cells were resuspended in retroviral supernatant at 0.7 3 106 cells/ml.
Cells were spun for 2.5 hr at 2600 rpm in 24-well plates. After infection, the cells
were resuspended in fresh media and cultured for 24 hr. Cells were sorted for
EGFP expression prior to analysis.
Conditional Deletion of Ebf1 in Fetal Liver Pro-B Cells
The floxed Ebf1 allele was generated by introduction of loxP sites flanking
exons 2 and 3 in ESCs by homologous recombination. These cells were used
for generating Ebf1+/fl mice. Ebf1+/fl mice were intercrossed and the resulting
Ebf1fl/flmicewere crossedwithRERT-Cremice, expressing a tamoxifen-induc-
ible ERT-Cre recombinase fusion protein under the control of a ubiquitous
promoter (Guerra et al., 2003), as well as with a Bcl2 transgenic mouse strain.
Further details of the Ebf1fl/fl mice will be described elsewhere. Total cell prep-
arations from livers of 16.5 days postcoitum (dpc) embryoswere cultured in the
presence of OP-9 bonemarrow stromal cells and Il7 until a pure pro-B cell pop-
ulationwasobtained. For inactivationofEbf1, theBcellswere treatedwith 2mM
4-hydroxy-tamoxifen for 24 hr, washed, and cultured for an additional 4 days.
ACCESSION NUMBERS
The ChIP-seq data set is available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE19971. The data sets of the loss-and gain-of function microarray analyses
are available under accession numbers GSE21454 and GSE21455, respec-
tively. The ChIP-on-chip data set is available under accession number
GSE21469.
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